Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are a diagnostics company with proprietary molecular and bioinformatics technology that we are applying to change disease management worldwide. Our cell-free DNA, or cfDNA, technology combines our novel molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell, with our statistical algorithms that incorporate data available from the broader scientific community to identify genetic variations covering a wide range of serious conditions with high accuracy and coverage.
In the company’s own words · 10-K filed Feb 27, 2026 · SEC EDGAR
Business segments
Q1 2026 · $696.6MThe company’s own SEC segment disclosure.
- US$685.6M98%
- EMEA$6.4M1%
- Americas Excluding United States$2.4M0%
- Asia Pacific And Other$2.2M0%
Natera, Inc. (NTRA) reported revenue of $753M in Q2 2026 (quarter ended June 30, 2026), up 38% from the same quarter a year earlier. That came with net loss of $67M. For the full year FY2025, revenue was $2.31B (+36% year on year) and net income −$208M. Its largest region in 2026-Q1 was US at $686M, 98% of the disclosed total, just ahead of EMEA at 0.9%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.
Diagnostics & Research
Ranks #1 of 29 by Smart Score